drugset / Trial / NCT07421856
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Phase 1/2
Not yet recruiting
24 enrolled
Hebei Senlang Biotechnology Inc., Ltd.
Institute of Hematology & Blood Diseases Hospital, China · collabPeking University People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To Evaluate Safety and Efficacy of S103 for Treating Relapsed or Refractory Multiple Myeloma
Timeline
- Start
- 2026-02-01
- Primary completion
- 2028-02-01
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SENL103 | Cell therapy | — | Intravenous |